Product Center
Ab&B Bio Tech CO., LTD. JS Innovation Vaccine Project is underway!
- Categories:Company news
- Author:
- Origin:
- Time of issue:2022-03-02
- Views:
(Summary description)New Year with a new atmosphere, embark on a new journey! We have laid the foundation! The Chinese New Year has a bright start
Ab&B Bio Tech CO., LTD. JS Innovation Vaccine Project is underway!
(Summary description)New Year with a new atmosphere, embark on a new journey!
We have laid the foundation!
The Chinese New Year has a bright start
- Categories:Company news
- Author:
- Origin:
- Time of issue:2022-03-02 16:15
- Views:
Information
New Year with a new atmosphere, embark on a new journey!
We have laid the foundation!
The Chinese New Year has a bright start
People are diligent, spring comes early, and striving is just the right time! The groundbreaking ceremony for the first season of projects in the Pharmaceutical High tech Zone (Gaogang District) and the Ab&B Bio Tech CO., LTD. JS innovative vaccine project was held at the site of the Zhonghui Yuantong project!
Ye Donghua, Deputy Mayor of Taizhou City Government, Secretary of the Party Working Committee of the Pharmaceutical High tech Zone, and Secretary of the Gaogang District Committee, sent good wishes to the project that has started construction, announced the start of the project, and participated in the groundbreaking ceremony.
Sun Hongjian, Director of the Management Committee of the Medical High tech Zone, Mayor of Gaogang District, and Secretary of the Party Working Committee of the Medical Park, expressed his earnest hopes and requirements for the innovative vaccine project that is about to fill the international gap in his speech: to implement it quickly and achieve results in production! Providing important support in the process of building a "domestic first, world famous" pharmaceutical city in China.
The Chairman and General Manager of the company, An Youcai, warmly welcomes all the leaders and guests present, and expresses sincere gratitude to all the people from all walks of life who have supported the company for many years! Emphasize that Zhonghui Yuantong will make every effort, work hard and never stop, and demonstrate its corporate responsibility and make due contributions in the process of building a national vaccine industry cluster highland in China Pharmaceutical City and enhancing the core competitiveness of the park's vaccine industry!
The industrialization project of the new influenza vaccine is one of the major projects in Jiangsu Province in 2022, with a total investment of 2 billion yuan. It is based on a high-level independent innovation of a new drug, the quadrivalent influenza virus subunit vaccine. In response to the call of the country to promote international cooperation in vaccines, it aims to build a world-class intelligent factory that meets international standards from a high starting point, and quickly achieve the industrialization of multiple innovative vaccine varieties!
Scan the QR code to read on your phone
Next:
None
Relevant information
-
Breaking through bottleneck technology, significant progress has been made in the research and development of new adjuvants
On August 25th, the R&D team of Yither Biotech (Shanghai) Co., Ltd, a wholly-owned subsidiary of Ab&B Bio Tech Co., Ltd (locally referred to as "Zhonghui Bio"), made a breakthrough in the field of innovative adjuvant research and development. The research results were published online in the internationally renowned journal "Journal of Drug Delivery Science and Technology" under the title "Dual functional Emulsifier Based Nano Emulsification Adjuvant Effectively Enhanced Immunogenicity of Recombinant Respiratory Syncytial Virus Vaccine in Mice". - Obtained recognition as one of the first offshore innovation centers for enterprises in Taizhou 08-14
- Recombinant herpes zoster vaccine (CHO cells) IND application approved 08-13
- IND application for quadrivalent influenza virus subunit vaccine (adjuvant) approved 07-30
- World Influenza Conference 2024 | Decoding new possibilities for the future of influenza vaccines 07-09